<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pathophysiology of heart failure: Neurohumoral adaptations
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pathophysiology of heart failure: Neurohumoral adaptations
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pathophysiology of heart failure: Neurohumoral adaptations
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wilson S Colucci, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen S Gottlieb, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 11, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The signs and symptoms of heart failure (HF) are due in part to compensatory mechanisms utilized by the body in an attempt to adjust for a primary deficit in cardiac function. In HF, neurohumoral adaptations have beneficial as well as maladaptive effects.
        </p>
        <p>
         The major neurohumoral adaptations that occur in HF, including activation of the sympathetic and renin-angiotensin-aldosterone systems; increased secretion of antidiuretic hormone, natriuretic peptides, and endothelin; and alterations in nitric oxide, will be reviewed here. Hemodynamic alterations in HF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3506.html" rel="external">
          "Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1968621940">
         <span class="h1">
          NEUROHUMORAL ADAPTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The principal neurohumoral systems involved in the response to HF are the sympathetic nervous system, the renin-angiotensin-aldosterone system, and antidiuretic hormone [
         <a href="#rid1">
          1-3
         </a>
         ]. Other vasoactive substances are also affected, including the vasoconstrictor endothelin and the vasodilators atrial natriuretic peptide, brain natriuretic peptide (BNP), and nitric oxide. These hormonal changes are seen with both systolic and diastolic dysfunction.
        </p>
        <p>
         Neurohumoral adaptations can contribute to maintenance of perfusion of vital organs in two ways [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of systemic pressure by vasoconstriction, resulting in redistribution of blood flow to vital organs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Restoration of cardiac output by increasing myocardial contractility and heart rate and by expansion of the extracellular fluid volume. Volume expansion is often effective because the heart can respond to an increase in venous return with an elevation in end-diastolic volume that results in a rise in stroke volume (via the Frank-Starling mechanism).
        </p>
        <p>
        </p>
        <p>
         In HF, these adaptations tend to overwhelm the vasodilatory and natriuretic effects of compensatory pathways including natriuretic peptides, nitric oxide, prostaglandins, and bradykinin [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p>
         There are a number of
         <strong>
          maladaptive
         </strong>
         consequences of persistent neurohumoral activation (
         <a class="graphic graphic_figure graphicRef61754" href="/z/d/graphic/61754.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The elevation in diastolic pressures is transmitted to the atria and to the pulmonary and systemic venous circulations; the ensuing elevation in capillary pressures promotes the development of pulmonary congestion and peripheral edema.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The increase in left ventricular (LV) afterload induced by the rise in peripheral resistance can both directly depress cardiac function due to the increase in LV afterload and, over time, enhance the rate of deterioration of myocardial function (
         <a class="graphic graphic_figure graphicRef71440" href="/z/d/graphic/71440.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The increases in contractility, heart rate, and LV afterload caused by neurohumoral adaptations can worsen or provoke coronary ischemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Catecholamines, angiotensin II, and aldosterone contribute to cardiac dysfunction by promoting the loss of myocytes by apoptosis, inducing maladaptive fetal isoforms of proteins involved in contraction, and causing myocardial hypertrophy and fibrosis.
        </p>
        <p>
        </p>
        <p>
         The relative importance of these beneficial and detrimental effects is not fully defined. However, the slowing of disease progression and improvement in survival observed with treatment with angiotensin converting enzyme inhibitors, angiotensin-receptor blockers, mineralocorticoid receptor antagonists, and beta blockers in patients with HF due to systolic dysfunction suggest that there is, over time, a net negative effect of the neurohumoral adaptations on ventricular function. The clinical benefits of inhibitors of these neurohormonal effects occur even in patients with mild or absent symptoms who may have only modest activation of these systems. (See
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3509.html" rel="external">
          "Management and prognosis of asymptomatic left ventricular systolic dysfunction", section on 'Approach to initial medical therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122165.html" rel="external">
          "Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of action"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3767556713">
         <span class="h2">
          Sympathetic nervous system
         </span>
         <span class="headingEndMark">
          —
         </span>
         The role of sympathetic nervous system activation in HF is complex, with both beneficial and adverse effects. Sympathetic nervous system activation is one of the first responses to a decrease in cardiac output, resulting in both increased release and decreased uptake of norepinephrine (NE) at adrenergic nerve endings. Downregulation or genetic loss-of-function variants of peripheral alpha-2 receptors, which normally inhibit NE release, may contribute to sympathetic activation in HF [
         <a href="#rid7">
          7
         </a>
         ]. Early in HF, catecholamine-induced augmentation of ventricular contractility and heart rate help maintain cardiac output, particularly during exercise. However, with progressive worsening of ventricular function, these mechanisms are no longer sufficient. In addition, intrinsic mechanisms that enhance ventricular contractility due to the normal force-frequency relationship are blunted in HF [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Increased sympathetic activity also leads to systemic and pulmonary vasoconstriction and enhanced venous tone, both of which initially contribute to the maintenance of blood pressure by increasing ventricular preload. Renal vasoconstriction (mediated by both NE and angiotensin II) occurs primarily at the efferent arteriole, producing an increase in filtration fraction that allows glomerular filtration to be relatively well maintained despite a fall in renal blood flow. Both NE and angiotensin II also stimulate proximal tubular sodium reabsorption, which contributes to the sodium retention characteristic of HF.
        </p>
        <p>
         Sympathetic activation is reflected by an increase in the plasma NE concentration, which correlates directly with the severity of the cardiac dysfunction and inversely with survival (
         <a class="graphic graphic_figure graphicRef62001" href="/z/d/graphic/62001.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
         In addition to systemic sympathetic activation, there is an increase in cardiac efferent sympathetic activity in patients with HF. This effect has been demonstrated by increased cardiac NE spillover (ie, elevated NE levels in cardiac veins) [
         <a href="#rid11">
          11,12
         </a>
         ]. A reduction in ventricular filling pressures reduces cardiac NE spillover [
         <a href="#rid13">
          13
         </a>
         ]. A similar effect is seen with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and may contribute to its clinical effects [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/968.html" rel="external">
          "Ventricular arrhythmias: Overview in patients with heart failure and cardiomyopathy"
         </a>
         .)
        </p>
        <p>
         The chronic increase in sympathetic activity also leads to downregulation and reduction in the density of the cardiac beta-adrenergic receptors and desensitization of the signaling cascade through which the receptors couple to physiologic events [
         <a href="#rid15">
          15
         </a>
         ]; this results in impaired inotropic and chronotropic responses. In addition, chronically increased stimulation of beta-adrenergic receptors may cause molecular and cellular abnormalities that contribute to the progression of myocardial dysfunction by the re-expression of fetal protein isoforms and the loss of cardiomyocytes due to apoptosis or necrosis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         The degree of sympathetic activation can be reduced by effective treatment of HF, as with administration of an angiotensin converting enzyme (ACE) inhibitor. In a study of 223 patients with mild or moderate HF, for example,
         <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">
          ramipril
         </a>
         therapy for 12 weeks significantly lowered the plasma NE concentration (compared with placebo) in patients with the most pronounced degree of neurohumoral activation [
         <a href="#rid17">
          17
         </a>
         ]. In the SOLVD trial, patients who had more marked neurohumoral activation, as reflected by plasma NE or angiotensin II, had a larger survival benefit with ACE inhibition than patients with less activation [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         These observations suggested that other methods of inhibiting sympathetic outflow might be of value in patients with HF, and led to the use of moxonidine, a drug that acts centrally to decrease sympathetic outflow. However, in the MOXCON trial, titration to a moxonidine target dose of 1.5 mg BID, which is associated with a decrease in plasma NE on the order of 50 percent [
         <a href="#rid19">
          19
         </a>
         ], was associated with an increase in deaths and adverse events [
         <a href="#rid20">
          20
         </a>
         ]. This experience showed that the role of sympathetic tone in HF is complex, and that generalized over-suppression of sympathetic tone can be harmful.
        </p>
        <p class="headingAnchor" id="H310366268">
         <span class="h3">
          Role of myocardial adrenergic receptors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The effects of the sympathetic nervous system on the myocardium are mediated by both beta- and alpha-adrenergic receptors in the myocardium. Stimulation of beta-1, and to a lesser extent, beta-2 adrenergic receptors on the cardiac myocyte increases contractility of the heart. These same receptors also mediate the adverse effects of pathologically increased catecholamines on myocyte viability. Myocyte apoptosis in HF has been attributed primarily to beta-1 adrenergic receptors that couple to stimulatory G protein (Gs)-dependent cAMP-mediated signaling [
         <a href="#rid21">
          21
         </a>
         ]. Excessive stimulation of beta-1 receptors may also lead to myocyte necrosis that is modulated by calcium overload and mitochondria permeability transition [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         In HF, there is a selective reduction in the density of beta-1 but not beta-2 receptors on the cardiac myocyte [
         <a href="#rid23">
          23,24
         </a>
         ]. As a result, the failing heart may be more dependent upon beta-2 adrenergic receptors for inotropic support. In addition, a polymorphism of the beta-2 receptor has been found in which a threonine (Thr) is replaced by isoleucine (Ile) at amino acid 164 [
         <a href="#rid25">
          25
         </a>
         ], resulting in a substantial decrease in the activity of the receptor. Transgenic mice expressing the Ile164 switch display depressed resting and agonist-stimulated contractile function compared with mice with the Thr164 receptor [
         <a href="#rid25">
          25
         </a>
         ]. In one series in humans, there was no difference in the frequency of these receptor genotypes in 259 patients with HF compared with 212 healthy controls [
         <a href="#rid26">
          26
         </a>
         ]. However, patients with the Ile164 receptor had a reduced one-year survival (42 versus 76 percent for those with the Thr164 receptor) and a relative risk of death or cardiac transplantation of 4.8 (p&lt;0.001). A possible mechanism is blunted cardiac beta-2 receptor responsiveness [
         <a href="#rid27">
          27
         </a>
         ]. In addition to helping to support the myocardial contractile response to sympathetic stimulation, beta-2 adrenergic receptors located on the cardiac myocyte exert an anti-apoptotic effect that opposes the pro-apoptotic action of beta-1 receptor stimulation [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         On the other hand, stimulation of pre-synaptic beta-2 receptors in the myocardium may mediate adverse effects. In contrast to presynaptic alpha-2 adrenergic receptors, which inhibit sympathetic NE release, presynaptic beta-2 adrenergic receptors stimulate NE release [
         <a href="#rid29">
          29
         </a>
         ]. Beta-blockers may act in part by reducing beta-2 receptor-mediated NE release in the heart, an effect that appears to be greater with nonselective versus selective beta blockers [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122165.html" rel="external">
          "Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of action", section on 'Beta blockers'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2152781860">
         <span class="h2">
          Renin-angiotensin system
         </span>
         <span class="headingEndMark">
          —
         </span>
         Each of the factors that stimulate renal renin release is activated in HF: decreased stretch of the glomerular afferent arteriole, reduced delivery of chloride to the macula densa, and increased beta-1 adrenergic activity (
         <a class="graphic graphic_figure graphicRef65116" href="/z/d/graphic/65116.html" rel="external">
          figure 4
         </a>
         ). Typically, plasma renin levels are elevated in patients with symptomatic HF (
         <a class="graphic graphic_figure graphicRef58128" href="/z/d/graphic/58128.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid1">
          1,3,30
         </a>
         ].
        </p>
        <p>
         In addition, angiotensin II can be synthesized locally at a variety of tissue sites including the heart, kidney, blood vessels, adrenal gland, and brain. For this reason, measurement of the plasma renin activity or angiotensin II concentration may underestimate tissue angiotensin II activity. As an example, the plasma renin activity is often normal in patients with stable, chronic HF, despite persistence of the low output state and renal sodium retention [
         <a href="#rid30">
          30
         </a>
         ]. Studies in experimental models of HF suggest that there may be increased activity of the intrarenal renin-angiotensin system in this setting [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Likewise, local cardiac angiotensin II and angiotensin converting enzyme production is increased in proportion to the severity of HF [
         <a href="#rid31">
          31-35
         </a>
         ].
        </p>
        <p>
         Angiotensin II has many similar actions to NE in HF, increasing sodium reabsorption (an effect mediated in part by enhanced release of aldosterone) and inducing systemic and renal vasoconstriction. Similar to NE, angiotensin II can act directly on myocytes and other cell types in the myocardium to promote pathologic remodeling via myocyte hypertrophy, re-expression of fetal protein isoforms, myocyte apoptosis, and alterations in the interstitial matrix. (See
         <a class="medical medical_review" href="/z/d/html/3506.html" rel="external">
          "Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling", section on 'Neurohormonal activation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3563348872">
         <span class="h3">
          Aldosterone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Secondary hyperaldosteronism in HF has been thought to reflect angiotensin II-mediated stimulation of the adrenal glands. However, there is also local production of aldosterone in the failing heart in proportion to the severity of HF [
         <a href="#rid35">
          35
         </a>
         ], an effect that is mediated by the induction of aldosterone synthase (CYP11B2) by angiotensin II in the failing ventricle [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Blockade of the adverse effects of aldosterone-induced stimulation of cardiac mineralocorticoid receptors is thought to contribute to the survival benefit associated with the administration of mineralocorticoid receptor antagonists in selected patients with HF. The effects of mineralocorticoid receptor antagonists on remodeling are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3506.html" rel="external">
          "Pathophysiology of heart failure with reduced ejection fraction: Hemodynamic alterations and remodeling", section on 'Neurohormonal activation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Mineralocorticoid receptor antagonist'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H143944901">
         <span class="h3">
          ACE gene polymorphism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma and tissue concentrations of ACE, and therefore of angiotensin II, are in part determined by the ACE gene. This gene may manifest insertion (I) or deletion (D) polymorphism and three genotypes (DD, ID, and II). Plasma and cardiac levels of ACE are 1.5- to 3-fold higher in patients with the DD compared with the II genotype; the values are intermediate in patients with ID genotype [
         <a href="#rid37">
          37
         </a>
         ]. The DD genotype of the ACE gene has been associated with a variety of adverse cardiovascular events, including conflicting data on impact on risk of coronary disease [
         <a href="#rid38">
          38-53
         </a>
         ].
        </p>
        <p>
         There may be an association between the DD genotype and increased mortality and reduced transplant-free survival in patients with HF due to idiopathic dilated cardiomyopathy [
         <a href="#rid44">
          44,45,54,55
         </a>
         ]. This difference may be abolished with beta blocker therapy as, in one study, transplant-free survival was equivalent in patients with the DD, ID, and II genotypes who were treated with a beta blocker [
         <a href="#rid45">
          45
         </a>
         ]. The adverse effect of the DD genotype on survival in patients with HF may be related to progression of HF rather than to arrhythmic sudden cardiac death [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1606606209">
         <span class="h2">
          Antidiuretic hormone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Activation of the carotid sinus and aortic arch baroreceptors by the low cardiac output in HF leads to enhanced release of antidiuretic hormone (ADH) and stimulation of thirst (see
         <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">
          "General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Role of ADH in volume regulation'
         </a>
         ). Elevated levels of ADH may contribute to the increase in systemic vascular resistance in HF via stimulation of the V1A receptor, which is found on vascular smooth muscle cells, and also promote water retention via the V2 receptor by enhancing water reabsorption in the collecting tubules. The combination of decreased water excretion and increased water intake via thirst often leads to a fall in the plasma sodium concentration. The severity of these defects tends to parallel the severity of the HF. As a result, the degree of hyponatremia is an important predictor of survival in these patients (
         <a class="graphic graphic_figure graphicRef55554" href="/z/d/graphic/55554.html" rel="external">
          figure 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2321.html" rel="external">
          "Hyponatremia in patients with heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H756018623">
         <span class="h2">
          Endothelin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endothelins are potent vasoconstrictor peptides produced by the vascular endothelium and cardiac myocytes which may contribute to the regulation of myocardial function, vascular tone, and peripheral resistance in HF. Plasma endothelin concentrations are increased in patients with HF; experimental studies suggest that angiotensin II may contribute to the high circulating levels in HF. Over the long term, high levels of endothelin (as with angiotensin II) may be deleterious to the heart due, for example, to pathologic remodeling [
         <a href="#rid56">
          56,57
         </a>
         ]. This has led to the evaluation of endothelin inhibition as a therapy for HF. However, clinical trials of endothelin receptor blockade in patients with HFrEF have demonstrated no benefit and some evidence of harm [
         <a href="#rid58">
          58-60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2770645278">
         <span class="h2">
          Natriuretic peptides
         </span>
         <span class="headingEndMark">
          —
         </span>
         Volume expansion and/or increased intra-cardiac pressures leads to increased atrial and ventricular strain which triggers the release of atrial natriuretic peptide (ANP), primarily from the atria, and BNP, primarily from the ventricles. Thus, plasma levels of these natriuretic peptides are elevated in patients with HF. The diagnostic and prognostic value of measuring levels of these hormones and related peptides is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure"
         </a>
         .)
        </p>
        <p>
         While plasma natriuretic peptide levels are useful biomarkers of disease severity, there is also evidence that natriuretic peptides, and in particular BNP, play an important beneficial role in the pathophysiology of HF. The natriuretic peptides exert a wide array of cellular and systemic effects which, by and large, oppose those of the adverse effects of the sympathetic nervous system and renin-angiotensin-aldosterone system. For example, they oppose vasoconstriction, promote salt and water excretion, and protect target organs from the adverse effects of NE and angiotensin. (See
         <a class="medical medical_review" href="/z/d/html/3486.html" rel="external">
          "Natriuretic peptide measurement in heart failure", section on 'Physiologic role in HF'
         </a>
         .)
        </p>
        <p>
         The combination drug
         <a class="drug drug_general" data-topicid="102505" href="/z/d/drug information/102505.html" rel="external">
          sacubitril-valsartan
         </a>
         exerts outcome effects superior to ACE inhibition in patients with HFrEF. A major action of sacubitril is inhibition of the degradation of natriuretic peptides. Whether sacubitril's effectiveness relates to enhanced natriuretic peptide levels or to vasodilation from other peptides remains uncertain. (See
         <a class="medical medical_review" href="/z/d/html/122165.html" rel="external">
          "Pharmacologic therapy of heart failure with reduced ejection fraction: Mechanisms of action", section on 'Angiotensin receptor-neprilysin inhibitor (ARNI)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H573934469">
         <span class="h2">
          Nitric oxide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nitric oxide (NO) is enzymatically formed from L-arginine by three isoforms of NO synthetase (NOS): neuronal-type (nNOS, NOS1), cytokine-inducible NOS (iNOS, NOS2), and the endothelial-type (eNOS, NOS3) [
         <a href="#rid61">
          61
         </a>
         ]. These enzymes differ markedly in their localization and function. Many cell types, most notably endothelial cells, constitutively express eNOS, generating relatively low levels of NO that are under tight control by regulatory factors. By contrast, iNOS is normally not expressed, but when induced by inflammatory cytokines can generate large amounts of NO far in excess of those made by eNOS. There may be alterations in all three isoforms of NOS in HF.
        </p>
        <p class="headingAnchor" id="H104309915">
         <span class="h3">
          In endothelium
         </span>
         <span class="headingEndMark">
          —
         </span>
         In endothelium - Chronic HF is associated with arterial endothelial dysfunction and impaired endothelium-dependent, flow-mediated dilation; the mechanism is probably a reduction in NO synthesis via eNOS [
         <a href="#rid62">
          62
         </a>
         ] as well as a decrease in endothelial release of and response to NO [
         <a href="#rid63">
          63,64
         </a>
         ]. By contrast, venous endothelial function and tone and basal and stimulated NO release from the venous capacitance bed are preserved [
         <a href="#rid65">
          65
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1532.html" rel="external">
          "Coronary endothelial dysfunction: Clinical aspects"
         </a>
         .)
        </p>
        <p>
         There is evidence of increased free radical formation in HF, and it is possible that these species inactivate NO. Support for this hypothesis comes from one study in which
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         improved endothelial function in patients with HF in association with an increased availability of NO [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1738126573">
         <span class="h3">
          In myocardium and skeletal muscle
         </span>
         <span class="headingEndMark">
          —
         </span>
         The level of NOS activity in the failing human myocardium is variable, likely reflecting the multiple types of NOS and the heterogeneity of myocardial failure. Increased levels of activity of eNOS [
         <a href="#rid67">
          67
         </a>
         ] and nNOS [
         <a href="#rid68">
          68
         </a>
         ], and increased NO production, have been observed within myocytes from patients with HF due to either an ischemic or nonischemic dilated cardiomyopathy [
         <a href="#rid67">
          67-70
         </a>
         ]. The expression of iNOS, in particular, appears to correlate with the level of tumor necrosis factor alpha (TNFa) [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         NO may exert detrimental as well as beneficial effects in the myocardium:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NO production lowered myocyte energy production by directly affecting mitochondrial function in an animal model [
         <a href="#rid72">
          72
         </a>
         ]. While this effect may limit energy availability, it may also reduce the generation of reactive oxygen radicals in the mitochondria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an animal model of myocardial infarction, eNOs limited LV remodeling and dysfunction [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NO can also affect basal myocardial function and can impair the inotropic response to beta-adrenergic receptor stimulation [
         <a href="#rid70">
          70,74-77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The induction of iNOS by inflammatory cytokines can generate high levels of NO that combine with superoxide to produce peroxynitrite, a reactive oxygen species that exerts harmful effects on the myocardium [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Inducible NO synthase gene expression and local NO production may also be increased within skeletal muscle of patients with HF [
         <a href="#rid79">
          79
         </a>
         ]. This response could contribute to a reduction in contractile performance and muscle wasting [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The principal neurohumoral systems involved in the response to heart failure (HF) are the sympathetic nervous system, the renin-angiotensin-aldosterone system, and antidiuretic hormone. Other vasoactive substances are also affected, including the vasoconstrictor endothelin and the vasodilators atrial natriuretic peptide, brain natriuretic peptide, and nitric oxide (NO). (See
         <a class="local">
          'Neurohumoral adaptations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the short term, neurohumoral activation is beneficial in patients with HF since the elevations in cardiac contractility and vascular resistance and renal sodium retention tend to restore the cardiac output and tissue perfusion toward normal. However, deleterious effects may predominate over the long term, leading to pulmonary and peripheral edema, increased afterload, pathologic myocardial remodeling, and more rapid progression of myocardial dysfunction. The ability of angiotensin converting enzyme inhibitors and beta blockers to improve survival and slow the progression of the HF is compatible with this hypothesis. (See
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NO is enzymatically formed from L-arginine by three isoforms of NO synthetase (NOS): neuronal-type (nNOS, NOS1), cytokine-inducible NOS (iNOS, NOS2), and the endothelial-type (eNOS, NOS3). There may be alterations in all three isoforms of NOS in HF. (See
         <a class="local">
          'Nitric oxide'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Francis GS, Goldsmith SR, Levine TB, et al. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23:1410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4:2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Logeart D, Tabet JY, Hittinger L, et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008; 127:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001; 96:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal A, Esler MD, Socratous F, Kaye DM. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol 2001; 37:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhargava V, Shabetai R, Mathiäsen RA, et al. Loss of adrenergic control of the force-frequency relation in heart failure secondary to idiopathic or ischemic cardiomyopathy. Am J Cardiol 1998; 81:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107:1278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994; 23:570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye DM, Lefkovits J, Jennings GL, et al. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995; 26:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Azevedo ER, Newton GE, Floras JS, Parker JD. Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure. Circulation 2000; 101:2053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye DM, Dart AM, Jennings GL, Esler MD. Antiadrenergic effect of chronic amiodarone therapy in human heart failure. J Am Coll Cardiol 1999; 33:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nozawa T, Igawa A, Yoshida N, et al. Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats. Circulation 1998; 97:2359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 1998; 98:1329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigurdsson A, Amtorp O, Gundersen T, et al. Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group. Br Heart J 1994; 72:422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SOLVD Investigators, Yusuf S, Pitt B, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swedberg K, Bristow MR, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002; 105:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003; 5:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vatner DE, Asai K, Iwase M, et al. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol 1999; 83:80H.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakayama H, Chen X, Baines CP, et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007; 117:2431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986; 59:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altschuld RA, Starling RC, Hamlin RL, et al. Response of failing canine and human heart cells to beta 2-adrenergic stimulation. Circulation 1995; 92:1612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turki J, Lorenz JN, Green SA, et al. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci U S A 1996; 93:10483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102:1534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodde OE, Büscher R, Tellkamp R, et al. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 2001; 103:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. Circulation 1999; 100:2210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newton GE, Parker JD. Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996; 94:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992; 90:1523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995; 76:18D.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dostal DE, Baker KM. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 1993; 153:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silvestre JS, Heymes C, Oubénaïssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99:2694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 1995; 92:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto YM, van Gilst WH, Kingma JH, Schunkert H. Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol 1995; 25:1622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oosterga M, Voors AA, de Kam PJ, et al. Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. Circulation 1997; 95:2607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schunkert H, Hense HW, Holmer SR, et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994; 330:1634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celentano A, Mancini FP, Crivaro M, et al. Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol 1999; 83:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tesson F, Dufour C, Moolman JC, et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997; 29:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery HE, Clarkson P, Dollery CM, et al. Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training. Circulation 1997; 96:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersson B, Sylvén C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Solà J, Nicolás JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med 2002; 137:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol 1998; 31:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfohl M, Koch M, Prescod S, et al. Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study. Eur Heart J 1999; 20:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 2000; 355:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332:706.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz J, Blanché H, Cohen N, et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 1994; 91:3662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Malley JP, Maslen CL, Illingworth DR. Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. Circulation 1998; 97:1780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raynolds MV, Bristow MR, Bush EW, et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedi MS, Postava LA, Murali S, et al. Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism. J Cardiovasc Electrophysiol 2004; 15:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishima T, Tanimura M, Suzuki G, et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000; 35:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleland JG, Coletta AP, Freemantle N, et al. Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER. Eur J Heart Fail 2005; 7:931.
          </a>
         </li>
         <li class="breakAll">
          Data presented at American College of Cardiology 51st Annual Session, Atlanta, Georgia, 2002.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Förstermann U, Closs EI, Pollock JS, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999; 99:2113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996; 28:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nightingale AK, Blackman DJ, Ellis GR, et al. Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction. J Am Coll Cardiol 2001; 37:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 97:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein B, Eschenhagen T, Rüdiger J, et al. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure. J Am Coll Cardiol 1998; 32:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Damy T, Ratajczak P, Shah AM, et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 2004; 363:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haywood GA, Tsao PS, von der Leyen HE, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996; 93:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drexler H, Kästner S, Strobel A, et al. Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 1998; 32:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comini L, Bachetti T, Agnoletti L, et al. Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha. Eur Heart J 1999; 20:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tatsumi T, Matoba S, Kawahara A, et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J Am Coll Cardiol 2000; 35:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scherrer-Crosbie M, Ullrich R, Bloch KD, et al. Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001; 104:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hare JM, Loh E, Creager MA, Colucci WS. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995; 92:2198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto S, Tsutsui H, Tagawa H, et al. Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure. Circulation 1997; 95:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 1998; 97:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinke T, Takaoka H, Takeuchi M, et al. Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101:1925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271:C1424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riede UN, Förstermann U, Drexler H. Inducible nitric oxide synthase in skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 1998; 32:964.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3481 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6147109" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The neurohumoral axis in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2956452" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Renal and circulatory mechanisms in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7909822" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965544" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cardiorenal syndrome in acute decompensated heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17651843" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Transient worsening of renal function during hospitalization for acute heart failure alters outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11805379" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pathophysiology of sodium and water retention in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11300430" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9605055" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Loss of adrenergic control of the force-frequency relation in heart failure secondary to idiopathic or ischemic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6382011" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12628948" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8113536" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7594040" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Adverse consequences of high sympathetic nervous activity in the failing human heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10790346" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Reducing cardiac filling pressure lowers norepinephrine spillover in patients with chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10334423" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Antiadrenergic effect of chronic amiodarone therapy in human heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9639381" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Dual-tracer assessment of coupling between cardiac sympathetic neuronal function and downregulation of beta-receptors during development of hypertensive heart failure of rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9751683" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7818958" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2057034" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11956122" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14607206" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10750593" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17694179" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2876788" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7664448" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Response of failing canine and human heart cells to beta 2-adrenergic stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8816827" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9788966" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11222464" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10577992" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8759076" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Acute effects of beta 1-selective and nonselective beta-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7006851" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1401084" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7495212" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10506489" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8386920" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Tissue renin-angiotensin system in myocardial hypertrophy and failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136688" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Aldosterone production is activated in failing ventricle in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10338465" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7664416" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7759715" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9193426" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8177269" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10215283" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9140839" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264477" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Association of angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physical training.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8752809" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11273991" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12204015" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9561998" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10462466" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1328889" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10841123" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7854377" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8170965" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9603531" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8105309" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15485441" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8934519" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Inhibition of myocardial endothelin pathway improves long-term survival in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10636284" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16087144" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16087144" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical trials update from the American College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15276394" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7515853" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10217650" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1914099" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Endothelium-dependent vasodilation is attenuated in patients with heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8772743" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11263609" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Preservation of venous endothelial function in the forearm venous capacitance bed of patients with chronic heart failure despite arterial endothelial dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9468210" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9809923" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15110495" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Increased neuronal nitric oxide synthase-derived NO production in the failing human heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8653828" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Expression of inducible nitric oxide synthase in human heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768717" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10493849" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor-alpha.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10758978" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11551881" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7554202" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9054836" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Role of myocyte nitric oxide in beta-adrenergic hyporesponsiveness in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9445168" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10779458" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Nitric oxide spares myocardial oxygen consumption through attenuation of contractile response to beta-adrenergic stimulation in patients with idiopathic dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8944624" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9768718" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Inducible nitric oxide synthase in skeletal muscle of patients with chronic heart failure.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
